Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock
Thomas F. Kearns, Jr. Insider Alerts

Get notified the next time Thomas F. Kearns, Jr. buys or sells FibroGen stock. Enter your email address below to get our daily insider buying and selling report.

Thomas F. Kearns, Jr. Insider Information

Director of FibroGen


Thomas F. Kearns, Jr. has served on our board of directors since November 1996, as lead independent director from June 2017 until August 2019, and as Chairperson of our board of directors from August 2019 until January 2020. Mr. Kearns is a retired Partner of The Bear Stearns Companies, Inc., an investment banking firm, where he was an investment banker in the healthcare area from 1974 until 1987. Prior to his career at Bear Stearns, Mr. Kearns worked for Merrill Lynch, an investment banking firm, from January 1959 until August 1969. Mr. Kearns was Chairman of the National Advisory Board of Carolina Performing Arts at the University of North Carolina from 2008 until 2015. Mr. Kearns was a Trustee of the University of North Carolina Foundation and Endowment Fund for 16 years. He served on the board of directors of Biomet Inc. from January 1980 until May 2005, and he served on the board of directors of Franklin Street Partners from 2013 until 2018. He received his B.A. in History from the University of North Carolina.

What is Thomas F. Kearns, Jr.'s net worth?

The estimated net worth of Thomas F. Kearns, Jr. is at least $2.00 million as of March 11th, 2021. Mr. Kearns, Jr. owns 166,164 shares of FibroGen stock worth more than $1,997,291 as of November 30th. This net worth evaluation does not reflect any other assets that Mr. Kearns, Jr. may own. Learn More.

How do I contact Thomas F. Kearns, Jr.?

The corporate mailing address for Mr. Kearns, Jr. and other FibroGen executives is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. FibroGen can also be reached via phone at (415) 978-1200 and via email at [email protected]

Has Thomas F. Kearns, Jr. been buying or selling shares of FibroGen?

Thomas F. Kearns, Jr. has not been actively trading shares of FibroGen over the course of the past ninety days. Most recently, Thomas F. Kearns, Jr. sold 13,100 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $11.58, for a transaction totalling $151,698.00.

Who are FibroGen's active insiders?

FibroGen's insider roster includes Pat Cotroneo (CFO), Thomas Kearns, Jr. (Director), and Thane Wettig (Insider).

Are insiders buying or selling shares of FibroGen?

In the last year, FibroGen insiders bought shares 1 times. They purchased a total of 3,100 shares worth more than $35,743.00. In the last year, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 65,571 shares worth more than $2,216,374.52. The most recent insider tranaction occured on September, 15th when Director Thomas F Kearns Jr sold 13,100 shares worth more than $151,698.00. Insiders at FibroGen own 3.0 % of the company.

Information on this page was last updated on 9/15/2021.

Thomas F. Kearns, Jr. Insider Trading History at FibroGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Sell13,100$11.58$151,698.00View SEC Filing Icon  
3/11/2021Sell18,000$35.02$630,360.00166,164View SEC Filing Icon  
3/19/2020Sell18,000$23.17$417,060.00161,464View SEC Filing Icon  
3/12/2018Sell18,000$55.00$990,000.00135,064View SEC Filing Icon  
11/15/2017Sell18,000$45.22$813,960.00156,564View SEC Filing Icon  
6/6/2017Sell18,000$28.71$516,780.00156,564View SEC Filing Icon  
11/18/2016Sell18,000$22.40$403,200.00165,564View SEC Filing Icon  
1/21/2016Sell1,572$22.08$34,709.76160,564View SEC Filing Icon  
See Full Table

Thomas F. Kearns, Jr. Buying and Selling Activity at FibroGen

This chart shows Thomas F Kearns Jr's buying and selling at FibroGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

FibroGen Company Overview

FibroGen logo
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $12.02
Low: $11.93
High: $12.57

50 Day Range

MA: $11.36
Low: $9.93
High: $13.15

2 Week Range

Now: $12.02
Low: $9.88
High: $57.21

Volume

824,340 shs

Average Volume

1,048,508 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96
Investors See Opportunity in Huge Global Demand for Lithium
The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.
Put this company on your investing radar today.